Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

The role of red blood cell lifespan in evaluating the condition of patients with paroxysmal nocturnal hemoglobinuria treated with complement inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

LYLei YeFZFengkui Zhang

Discussion

Loading...

Member takes

Overview

Prospective cohort study reveals reduced hemolysis and improved hemoglobin in patients with paroxysmal nocturnal hemoglobinuria treated with Eculizumab, indicating enhanced treatment efficacy.

Key Points

  • Patients with paroxysmal nocturnal hemoglobinuria showed a median hemoglobin increase during treatment, reflecting improved disease management.
  • Lactate dehydrogenase levels significantly decreased by 1689 U/L, suggesting reduced hemolytic activity across various complement inhibitor therapies.
  • Prospective analysis incorporated RBC lifespan as a gold standard measure, linking it closely with hemoglobin dynamics and treatment outcomes in PNH patients.
  • Various complement inhibitors demonstrated differing treatment efficacy levels, underlining the importance of individualized therapy options for PNH.

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df6dhttps://doi.org/10.1182/blood-2025-4971
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria (PNH)2025
  2. 2Correlation between efficacy, clonal dynamics evolution, and development of bone marrow failure in PNH/AA syndrome treated with complement inhibitors: A single-center cohort study2025
  3. 3[New treatment strategies for paroxysmal nocturnal hemoglobinuria: drug selection in the era of novel complement inhibitors].2025
  4. 4Clinical Outcomes and Disease Management for Patients with Paroxysmal Nocturnal Haemoglobinuria in China: Results from a Real-World Study2025
  5. 5Real-world data on breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with proximal and terminal complement inhibitors.2025